Your browser doesn't support javascript.
loading
Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
Ito, Takanori; Morooka, Hikaru; Takahashi, Hirokazu; Fujii, Hideki; Iwaki, Michihiro; Hayashi, Hideki; Toyoda, Hidenori; Oeda, Satoshi; Hyogo, Hideyuki; Kawanaka, Miwa; Morishita, Asahiro; Munekage, Kensuke; Kawata, Kazuhito; Tsutsumi, Tsubasa; Sawada, Koji; Maeshiro, Tatsuji; Tobita, Hiroshi; Yoshida, Yuichi; Naito, Masafumi; Araki, Asuka; Arakaki, Shingo; Kawaguchi, Takumi; Noritake, Hidenao; Ono, Masafumi; Masaki, Tsutomu; Yasuda, Satoshi; Tomita, Eiichi; Yoneda, Masato; Tokushige, Akihiro; Ishigami, Masatoshi; Kamada, Yoshihiro; Ueda, Shinichiro; Aishima, Shinichi; Sumida, Yoshio; Nakajima, Atsushi; Okanoue, Takeshi.
Afiliação
  • Ito T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Morooka H; Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Takahashi H; Liver Center, Saga University Hospital, Saga, Japan.
  • Fujii H; Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Iwaki M; Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Hayashi H; Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
  • Toyoda H; Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Oeda S; Liver Center, Saga University Hospital, Saga, Japan.
  • Hyogo H; Department of Laboratory Medicine, Saga University Hospital, Saga, Japan.
  • Kawanaka M; Department of Gastroenterology, JA Hiroshima Kouseiren General Hospital, Hiroshima, Japan.
  • Morishita A; Hyogo Life Care Clinic Hiroshima, Hiroshima, Japan.
  • Munekage K; Department of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School, Okayama, Japan.
  • Kawata K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
  • Tsutsumi T; Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan.
  • Sawada K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.
  • Maeshiro T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Tobita H; Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Asahikawa Medical University, Asahikawa, Japan.
  • Yoshida Y; First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.
  • Naito M; Division of Hepatology, Shimane University Hospital, Izumo, Japan.
  • Araki A; Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan.
  • Arakaki S; Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan.
  • Kawaguchi T; Division of Hepatology, Shimane University Hospital, Izumo, Japan.
  • Noritake H; First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.
  • Ono M; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Masaki T; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.
  • Yasuda S; Division of Innovative Medicine for Hepatobiliary and Pancreatology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
  • Tomita E; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
  • Yoneda M; Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Tokushige A; Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
  • Ishigami M; Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kamada Y; Department of Cardiovascular Medicine and Hypertension, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Ueda S; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Aishima S; Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Sumida Y; Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
  • Nakajima A; Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.
  • Okanoue T; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
J Gastroenterol Hepatol ; 38(10): 1832-1839, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37596843
ABSTRACT
BACKGROUND AND

AIMS:

Both fibrosis status and body weight are important for assessing prognosis in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to identify population clusters for specific clinical outcomes based on fibrosis-4 (FIB-4) index and body mass index (BMI) using an unsupervised machine learning method.

METHODS:

We conducted a multicenter study of 1335 biopsy-proven NAFLD patients from Japan. Using the Gaussian mixture model to divide the cohort into clusters based on FIB-4 index and BMI, we investigated prognosis for these clusters.

RESULTS:

The cohort consisted of 223 cases (16.0%) with advanced fibrosis (F3-4) as assessed from liver biopsy. Median values of BMI and FIB-4 index were 27.3 kg/m2 and 1.67. The patients were divided into four clusters by Bayesian information criterion, and all-cause mortality was highest in cluster d, followed by cluster b (P = 0.001). Regarding the characteristics of each cluster, clusters d and b presented a high FIB-4 index (median 5.23 and 2.23), cluster a presented the lowest FIB-4 index (median 0.78), and cluster c was associated with moderate FIB-4 level (median 1.30) and highest BMI (median 34.3 kg/m2 ). Clusters a and c had lower mortality rates than clusters b and d. However, all-cause of death in clusters a and c was unrelated to liver disease.

CONCLUSIONS:

Our clustering approach found that the FIB-4 index is an important predictor of mortality in NAFLD patients regardless of BMI. Additionally, non-liver-related diseases were identified as the causes of death in NAFLD patients with low FIB-4 index.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão